MedImmune for sale?
This article was originally published in The Gray Sheet
Executive Summary
Firm will continue evaluating strategic alternatives following "indications of interest by major pharmaceutical companies," and some investors "dissatisfaction with the company's short-term stock price performance," MedImmune says April 12. The FluMist nasal-inhaler manufacturer has hired Goldman Sachs and Dewey Ballantine LLP to assist in the process...